Adverse events · Children who were regular dental attenders with caries-free first or second primary molars (public health service clinic, Brazil)
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · Children with caries-free or non-cavitated carious lesion primary molars, aged 3-7 years (paediatric department, dental hospital, France)
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · People aged 12 years and over with painful TMD lasting 3 months or longer
1 finding from 1 review
Adverse events · Adults (>18 years) having permanent tooth extraction (predominantly mandibular third molars)
1 finding from 1 review
3 trials reported no adverse events. 1 study reported adverse events (alterations in taste, bad taste, staining) in 24/62 in chlorhexidine group versus 0/40 in placebo group, Peto OR = 8.42 (95% CI 3.31 to 21.39). A…
6 studies
GRADE not reported
Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Adverse events · children younger than two years of age with bilateral congenital cataracts
1 finding from 1 review
Adverse events · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children aged up to 16 years with ARTIs
It is very uncertain whether homeopathic medicinal products (non‐individualised treatment) changes adverse events compared with placebo or usual care (very low certainty).
1 finding from 1 review
Adverse events · children aged up to 16 years with ARTIs
1 finding from 1 review
Adverse events · children aged up to 16 years with ARTIs
Homeopathic medicinal products (individualised treatment) showed no clear difference in adverse events compared with placebo or usual care (moderate certainty).
1 finding from 1 review
Adverse events · children with asymptomatic flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children with asymptomatic flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children with juvenile idiopathic arthritis and flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children with juvenile idiopathic arthritis and flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children with asymptomatic flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in adverse events compared with higher doses (low certainty).
1 finding from 1 review
Adverse events · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
Naloxone + oxycodone prolonged release tablets showed no clear difference in adverse events compared with oxycodone prolonged‐released tablets (low certainty).
1 finding from 1 review
Adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review